BullFrog AI Holdings, Inc. announced that it has identified multiple potential therapeutic targets, including three novel targets, for colorectal cancer using the Company's proprietary AI-driven platform, bfLEAP??. The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a genomics research and innovation institution.JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | -5.90% |
|
+30.19% | -36.50% |
1st Jan change | Capi. | |
---|---|---|
-36.50% | 17.27M | |
+23.52% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+37.34% | 33.02B | |
-6.30% | 27.9B | |
+19.34% | 27.63B | |
+47.63% | 14.37B | |
+43.70% | 13.45B | |
+0.44% | 12.03B |
- Stock Market
- Equities
- BFRG Stock
- News Bullfrog AI Holdings, Inc.
- BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP? Platform